Scilex Holding (SCLX) Assets Average (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Assets Average of $329.3 million for Q1 2026, up 283.07% year-over-year from $86.0 million in Q1 2025, and up 2.77% on a QoQ basis from $320.4 million in Q4 2025.
Scilex Holding (SCLX) Assets Average (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Assets Average for 6 consecutive years, with $329.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 283.07% year-over-year to $329.3 million; the TTM figure through Mar 2026 stood at $329.3 million (up 283.07% YoY), while the FY2025 annual figure was $229.0 million, up 135.73% from the prior year.
- Assets Average came in at $329.3 million for Q1 2026 at Scilex Holding, up from $320.4 million in the prior quarter.
- The five-year high for Assets Average was $329.3 million in Q1 2026, with the low at $81.4 million in Q2 2025.
- Average Assets Average over 5 years is $132.0 million, with a median of $102.5 million recorded in 2024.
- Across the five-year window, Assets Average slipped 24.98% in 2023 and jumped 283.07% in 2026, its largest moves.
- Year by year, Assets Average stood at $94.0 million in 2022, then slipped by 3.27% to $90.9 million in 2023, then advanced by 6.35% to $96.7 million in 2024, then surged by 231.39% to $320.4 million in 2025, then gained by 2.77% to $329.3 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $329.3 million, $320.4 million, and $179.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 114.53 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 200.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 135.21 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 114.04 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | 329.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 329.31 Mn |
| Dec 31, 2025 | 320.43 Mn |
| Sep 30, 2025 | 179.82 Mn |
| Jun 30, 2025 | 81.37 Mn |
| Mar 31, 2025 | 85.96 Mn |
| Dec 31, 2024 | 96.69 Mn |
| Sep 30, 2024 | 102.49 Mn |
| Jun 30, 2024 | 97.89 Mn |
| Mar 31, 2024 | 96.27 Mn |
| Dec 31, 2023 | 90.92 Mn |
| Sep 30, 2023 | 103.50 Mn |
| Jun 30, 2023 | 106.26 Mn |
| Mar 31, 2023 | 86.29 Mn |
| Dec 31, 2022 | 93.99 Mn |
| Sep 30, 2022 | 121.88 Mn |
| Jun 30, 2022 | 141.64 Mn |
| Mar 31, 2022 | 109.45 Mn |
| Dec 31, 2021 | 108.79 Mn |
| Sep 30, 2021 | 139.77 Mn |
| Jun 30, 2021 | 139.98 Mn |